Beam Therapeutics Inc. (Nasdaq: BEAM), a biotechnology company developing precision genetic medicines through base editing, ...

Shares of Akebia Therapeutics were trading at $2.01 as of November 06. Over the last 52-week period, shares are up 1.26%.

Announced in May 2025, the Dyno Frontiers Program helps gene therapy innovators prove the therapeutic potential of their ...

CordenPharma and Viking Therapeutics (VKTX) sign multi-year strategic partnership to support the commercial demand of Viking Therapeutics' GLP-1 drug candidate VK2735. CordenPharma provides ...

As the digital health market evolves, Omada Health's comprehensive approach—merging pharmaceutical interventions with behavioral science and technology—positions the company to potentially become the ...

First anticipated ZEVASKYN® patient treatment shifted to 4Q 2025 following implementation of optimized release assay -- ...

Transcend is developing one of the most promising psychoactive compounds – with previous human experience to treat PTSD NEW YORK, Feb. 23, 2023 /PRNewswire/ -- Transcend Therapeutics, a biotechnology ...

Akebia Therapeutics®, Inc. (Nasdaq: AKBA), a biopharmaceutical company with the purpose to better the lives of people ...

TG Therapeutics (NASDAQ: TGTX) will release its quarterly earnings report on Monday, 2025-11-03. Here's a brief overview for investors ahead of the announcement. Analysts anticipate TG Therapeutics to ...

Transcend is developing one of the most promising psychoactive compounds – with previous human experience to treat PTSD Transcend is developing one of the most promising psychoactive compounds – with ...